There are 2949 resources available
749P - Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032
Presenter: Padmanee Sharma
Session: E-Poster Display
Resources:
Abstract
750P - Erdafitinib (ERDA) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC): Subgroup analyses of long-term efficacy outcomes of a pivotal phase II trial (BLC2001)
Presenter: Andrea Necchi
Session: E-Poster Display
Resources:
Abstract
751P - Analysis of circulating tumor DNA (ctDNA) from the phase II BLC2001 trial of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC) to identify markers of intrinsic resistance to fibroblast growth factor receptor (FGFR)-targeted therapy
Presenter: Arlene Siefker-Radtke
Session: E-Poster Display
Resources:
Abstract
752P - Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations
Presenter: Arlene Siefker-Radtke
Session: E-Poster Display
Resources:
Abstract
753P - Urine tumor DNA methylation assay enables early diagnosis, residual detection and recurrence monitoring for bladder cancer
Presenter: Xu Chen
Session: E-Poster Display
Resources:
Abstract
754P - Ibrutinib (Ibr) in combination with paclitaxel (Pac) has activity in patients (Pts) with advanced urothelial carcinoma (aUC): Final analysis of a phase Ib/II study
Presenter: Daniel Castellano Gauna
Session: E-Poster Display
Resources:
Abstract
755P - Comparative clinical efficacy of neoadjuvant (NACT) versus adjuvant chemotherapy (ACT) in the treatment of locally advanced penile cancer (PeCa): A proportional meta-analysis of case series
Presenter: Kevin Gallagher
Session: E-Poster Display
Resources:
Abstract
756P - Molecular subtyping and immune-gene signatures identify a subset of clinical T1 high-grade (cT1 HG) and cT2 bladder urothelial carcinoma (UC) as candidates for single-agent immune checkpoint inhibition (ICI)
Presenter: Andrea Necchi
Session: E-Poster Display
Resources:
Abstract
757P - An observational study of outcomes of patients (pts) with advanced urothelial carcinoma (UC) after anti-programmed death-(Ligand) 1 (PD-[L]1) therapy by fibroblast growth factor receptor gene alteration (FGFRa) status
Presenter: Arash Rezazadeh
Session: E-Poster Display
Resources:
Abstract
758P - Assessment of prognostic and predictive value of FGFR alterations (FGFRa) in a real-world cohort of patients (pts) with high-risk pT1 non-muscle-invasive bladder cancer (NMIBC)
Presenter: Johannes Breyer
Session: E-Poster Display
Resources:
Abstract